MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Hold” by Analysts

MindWalk Holdings Corp. (NASDAQ:HYFT) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $5.00.

HYFT has been the subject of several recent analyst reports. Wall Street Zen lowered MindWalk from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Zacks Research lowered MindWalk from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. JonesTrading started coverage on MindWalk in a research report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research note on Monday, July 20th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HYFT. Virtu Financial LLC purchased a new stake in MindWalk in the 4th quarter valued at about $51,000. Bridgeway Capital Management LLC bought a new position in MindWalk in the 4th quarter worth about $91,000. Bank of Montreal Can increased its position in shares of MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the period. XTX Topco Ltd increased its position in shares of MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Finally, Jane Street Group LLC raised its stake in shares of MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after acquiring an additional 96,018 shares in the last quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

MindWalk Trading Down 4.4%

HYFT stock opened at $1.29 on Friday. The stock has a market cap of $60.26 million, a PE ratio of -5.86 and a beta of 0.83. MindWalk has a 12 month low of $0.99 and a 12 month high of $3.25. The business’s 50-day moving average price is $1.55. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $3.03 million during the quarter. MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%. Sell-side analysts forecast that MindWalk will post -0.21 EPS for the current year.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.